David Tamang

2.2k total citations · 1 hit paper
37 papers, 1.8k citations indexed

About

David Tamang is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, David Tamang has authored 37 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 19 papers in Oncology and 12 papers in Hematology. Recurrent topics in David Tamang's work include Histone Deacetylase Inhibitors Research (16 papers), Protein Degradation and Inhibitors (12 papers) and Multiple Myeloma Research and Treatments (11 papers). David Tamang is often cited by papers focused on Histone Deacetylase Inhibitors Research (16 papers), Protein Degradation and Inhibitors (12 papers) and Multiple Myeloma Research and Treatments (11 papers). David Tamang collaborates with scholars based in United States, Luxembourg and Sierra Leone. David Tamang's co-authors include Simon S. Jones, Min Yang, Noopur Raje, Philip E. Bourne, Young‐Hee Kim, C. Lundegaard, Peng Wang, Alessandro Sette, Morten Nielsen and Jason Greenbaum and has published in prestigious journals such as Nucleic Acids Research, Journal of Clinical Oncology and Blood.

In The Last Decade

David Tamang

36 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

2012 488 citations Teru Hideshima, Andrew L. Kung et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Tamang United States	14	1.3k	637	401	362	151	37	1.8k
Marianne Kraus Switzerland	21	1.4k 1.0×	537 0.8×	441 1.1×	614 1.7×	471 3.1×	48	2.2k
Keyvan Rezaï France	21	1.5k 1.1×	499 0.8×	124 0.3×	640 1.8×	165 1.1×	78	2.3k
Uwe Schaefer United States	7	1.4k 1.1×	197 0.3×	620 1.5×	448 1.2×	190 1.3×	8	2.0k
Barbara Boone Belgium	15	582 0.4×	401 0.6×	423 1.1×	111 0.3×	223 1.5×	24	1.6k
Gábor Pál Hungary	25	736 0.6×	193 0.3×	761 1.9×	308 0.9×	124 0.8×	62	1.9k
Andrew L. Snow United States	28	747 0.6×	901 1.4×	1.4k 3.5×	198 0.5×	369 2.4×	63	2.5k
Dale R. Taylor United Kingdom	9	522 0.4×	285 0.4×	892 2.2×	229 0.6×	144 1.0×	12	1.6k
D McDonald United States	15	844 0.6×	167 0.3×	276 0.7×	129 0.4×	137 0.9×	28	1.3k
Kim L. Nelson Canada	14	444 0.3×	212 0.3×	598 1.5×	193 0.5×	105 0.7×	18	1.2k
Anna Skaletskaya United States	12	655 0.5×	258 0.4×	467 1.2×	192 0.5×	908 6.0×	22	1.6k

Countries citing papers authored by David Tamang

Since Specialization

Citations

This map shows the geographic impact of David Tamang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Tamang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Tamang more than expected).

Fields of papers citing papers by David Tamang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Tamang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Tamang. The network helps show where David Tamang may publish in the future.

Co-authorship network of co-authors of David Tamang

This figure shows the co-authorship network connecting the top 25 collaborators of David Tamang. A scholar is included among the top collaborators of David Tamang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Tamang. David Tamang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Berdeja, Jesús G., Min Yang, Noopur Raje, et al.. (2024). Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. Carolina Digital Repository (University of North Carolina at Chapel Hill).

Hellmann, Matthew D., Pasi A. Jänne, Mateusz Opyrchal, et al.. (2020). Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy. Clinical Cancer Research. 27(4). 1019–1028. 83 indexed citations

Tolcher, Anthony W., Michael L. Meyers, Dmitry I. Gabrilovich, et al.. (2018). Abstract CT179: Safety, efficacy, and immune correlates of alternative doses and schedules of entinostat combined with pembrolizumab in patients with advanced solid tumors - results from SNDX-275-0141 phase I trial. Cancer Research. 78(13_Supplement). CT179–CT179. 1 indexed citations

Bergh, Rafaël Van den, et al.. (2017). Knockdown and recovery of malaria diagnosis and treatment in Liberia during and after the 2014 Ebola outbreak. Public Health Action. 7(Supplement 1). S76–S81. 7 indexed citations

Moses, Francis, et al.. (2017). Management of malaria in children with fever in rural Sierra Leone in relation to the 2014–2015 Ebola outbreak. Public Health Action. 7(Supplement 1). S22–S26. 5 indexed citations

Squire, James Sylvester, et al.. (2017). The Ebola outbreak and staffing in public health facilities in rural Sierra Leone: who is left to do the job?. Public Health Action. 7(Supplement 1). S47–S54. 8 indexed citations

Vogl, Dan T., Noopur Raje, Sundar Jagannath, et al.. (2017). Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma. Clinical Cancer Research. 23(13). 3307–3315. 192 indexed citations

North, Brian J., et al.. (2017). Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor. PLoS ONE. 12(3). e0173507–e0173507. 40 indexed citations

Yee, Andrew J., William Bensinger, Jeffrey G. Supko, et al.. (2016). Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial. The Lancet Oncology. 17(11). 1569–1578. 162 indexed citations

10.

Shearstone, Jeffrey R., Olga Golonzhka, Apurva Chonkar, et al.. (2016). Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2. PLoS ONE. 11(4). e0153767–e0153767. 28 indexed citations

11.

Quayle, Steven N., et al.. (2015). Abstract 5380: Selective HDAC inhibition by ricolinostat (ACY-1215) or ACY-241 synergizes with IMiD® immunomodulatory drugs in Multiple Myeloma (MM) and Mantle Cell Lymphoma (MCL) cells. Cancer Research. 75(15_Supplement). 5380–5380. 4 indexed citations

12.

Kim, Young‐Hee, Julia Ponomarenko, Zhenggang Zhu, et al.. (2012). Immune epitope database analysis resource. Nucleic Acids Research. 40(W1). W525–W530. 396 indexed citations

13.

Santo, Loredana, Teru Hideshima, Andrew L. Kung, et al.. (2011). Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma. Blood. 118(21). 2908–2908. 2 indexed citations

14.

Tamang, David, et al.. (2009). Lipid‐dependent cytotoxicity by the lipase PLRP2 and by PLRP2‐positive cytotoxic T lymphocytes (CTLs). Cell Biochemistry and Function. 27(5). 296–308. 6 indexed citations

15.

Tamang, David, et al.. (2009). Regulation of perforin lysis: Implications for protein disulfide isomerase proteins. Cellular Immunology. 255(1-2). 82–92. 5 indexed citations

16.

Alves, B. R. C., J A Leong, David Tamang, et al.. (2009). Hydrolysis of tumor cell lipids after CTL-mediated death. International Immunology. 21(5). 543–553. 3 indexed citations

17.

Tamang, David, et al.. (2009). Pancreatic lipase-related protein 2 (PLRP2) induction by IL-4 in cytotoxic T lymphocytes (CTLs) and reevaluation of the negative effects of its gene ablation on cytotoxicity. Journal of Leukocyte Biology. 86(3). 701–712. 7 indexed citations

18.

Tamang, David, et al.. (2008). Low dose IL-15 induces snap arming of CD44low T lymphocytes in the absence of antigen. Cellular Immunology. 251(2). 93–101. 1 indexed citations

19.

Tamang, David, et al.. (2006). Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: Multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal. Cytokine. 36(3-4). 148–159. 55 indexed citations

20.

Tamang, David, Chiung-Yin Huang, I‐Yu Tsao, et al.. (2004). The use of a double subgenomic Sindbis virus expression system to study mosquito gene function: effects of antisense nucleotide number and duration of viral infection on gene silencing efficiency. Insect Molecular Biology. 13(6). 595–602. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact